BRUIN: First-in-Human Phase I Trial Investigating Non-Covalent BTK Inhibitor LOXO-305 in Pretreated B-Cell Malignancies

Source: 2019 American Society of Hematology Annual Meeting*
Download Slideset
December 7-10, 2019; Orlando, Florida
LOXO-305, a non-covalent BTK inhibitor, demonstrated preliminary antitumor activity and manageable safety in pretreated B-cell malignancies including those resistant to previous BTKi therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 193 KB
Released: December 19, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings